Navigation Links
EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
Date:6/18/2008

Experienced Biotech Business Development and Investment Banker Enhances

EntreMed's Senior Management Team

ROCKVILLE, Md., June 18 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the appointment of Mr. Thomas H. Bliss, Jr. as Senior Vice President, Corporate and Business Development. Mr. Bliss has been elected an executive officer by EntreMed's Board of Directors and will report to the Company's President and Chief Executive Officer, Mr. James S. Burns.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Most recently the Executive Director, Licensing at Amgen, Mr. Bliss brings nearly 20 years biotechnology business development and healthcare investment banking experience to EntreMed. In his most recent role at Amgen, Mr. Bliss was responsible for international licensing, licensing operations oversight and the coordination and communication of Amgen's China/India Research Activities Initiative. Previous to that, Mr. Bliss was responsible for directing all Amgen acquisition activity, including the acquisition of Abgenix. Prior to joining Amgen in 2004, Mr. Bliss served as Vice President, BioPharmaceuticals Business Development at Baxter BioScience, where he directed all licensing and acquisition activities.

Mr. Bliss' career in life science business development began in 1994 with Johnson & Johnson where he provided analytical support for all franchises and participated in the creation of billion dollar cardiovascular access and orthopedic businesses. The first
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
2. EntreMed Appoints Senior Vice President of Research and Development
3. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
4. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
5. EntreMed to Present at BIO CEO and Investor Conference
6. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
7. EntreMed Announces 2008 Corporate and Clinical Program Priorities
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
11. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... , AMSTERDAM, November 30 ...today that the first patients have been enrolled i...th ATIR(TM). The study is,designed to show reducti...,year following an allogeneic stem cell transplant... blood cancer patients eligible for an allogeneic,...
(Date:11/30/2009)... , ROCKVILLE, Md., Nov. 30 /PRNewswire-FirstCa...day it has completed enrollment in the Phase II cl...2008/2009 recommended strains) VLP vaccine candida...er adults). This randomized, double-blind, active...ility and immunogenicity of two different doses (1...
(Date:11/30/2009)... , SEATTLE, Nov. 30 /PRNewswire-FirstCall...: CTIC) announced today that its new class of plat...ates, demonstrated a stronger anti-tumor potency a...um-based compounds as well as the ability to overc...e results were presented in a paper titled "Novel ...
(Date:11/30/2009)... , LONDON, November 30 /PRNewswire...ompany, was named Europe,s fastest growing,Biotech...ny in the Deloitte,2009 Technology Fast 500 for EM...is annual ranking is based on a companies, five-ye...a rate of 8,318% over this period. This,achievemen...
Breaking Biology Technology:Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3ApaTech is Europe's Fastest Growing Lifescience Company 2ApaTech is Europe's Fastest Growing Lifescience Company 3ApaTech is Europe's Fastest Growing Lifescience Company 4
...LE, Virginia, April 2 Biovista Inc. today,announc...osis (MS), has shown,significant positive results ...myelitis (EAE) murine model of MS. BVA-101, an exi... aimed at neuroprotection, was shown to,have both ... in this well,established model of MS. , "We a...
... 2 Nuevolution A/S today announced that Merck &am...ase of the collaboration agreement announced in Ju...cs(R) drug discovery technology to identify novel ... , , By entering the second phase, Merck gains ac...rary of small molecule drug candidates. In additi...
..., April 1 On April 1, 2009, Xmark Opportunity Par...ger of Xmark Opportunity Fund, L.P. and Xmark Oppo...he Board of Directors of Icagen, Inc. (Nasdaq: I...UNITY PARTNERS, LLC, ... Suite 201, ...
Other Biology Technology:Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis 2Nuevolution Announces Progress in Its Collaboration With Merck & Co. Inc. 2Xmark Requests That Icagen Oust Its CEO and Pursue Strategic Alternatives, and Calls on Board Members to Resign 2
(Date:11/30/2009)...ia, Nov. 30 Neurotechnology ( http...recision biometric identification technologies, ha...product line: VeriLook 4.0 Software Development ... 3.1 SDK for large-scale multi-biometric and autom...panded capabilities in VeriLook 4.0 provide enhanc...
(Date:11/26/2009)...t a way of using recordings of birdsong to accurat...the first time sound recordings from a microphone ... of bird species, populations. Because the new tec...,s Journal of Applied Ecology , will also work wi... our ability to monitor whale and dolphin numbers....
(Date:11/26/2009)...hylococcus Aureus ) and other drug-resistant bacte...sma prototype devices have been developed to offer...tails. , Two prototype devices have been develop... (e.g. hands and feet) in hospitals and public spa...nother to shoot bacteria-killing agents into infes...
Breaking Biology News(10 mins):New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 3Ecologists sound out new solution for monitoring cryptic species 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3TGen led team is 1 of 7 selected for 241 million skin cancer grants 53469 1TGen led team is 1 of 7 selected for 241 million skin cancer grants 53469 2TGen led team is 1 of 7 selected for 241 million skin cancer grants 53469 3TGen led team is 1 of 7 selected for 241 million skin cancer grants 53469 4IDEAL LIFEs Remote Monitoring System Benefits Rural North Carolina Communities 53465 1IDEAL LIFEs Remote Monitoring System Benefits Rural North Carolina Communities 53465 2IDEAL LIFEs Remote Monitoring System Benefits Rural North Carolina Communities 53465 3Yongye International Announces Branded Store Network Increases Over 40 25 to 5 000 Stores 13323 1Yongye International Announces Branded Store Network Increases Over 40 25 to 5 000 Stores 13323 2Yongye International Announces Branded Store Network Increases Over 40 25 to 5 000 Stores 13323 3
... Smithsonian ecologist Kathy Boomer suggests it is...ed management. Boomer has been examining the tools...ediment runs into the Chesapeake Bay, and by her a...uthored by SERC ecological modeler Donald Weller a.../February issue of the Journal of Environmental Qu...
...08) -- The Prostate Cancer Foundation, largely thr... million to four institutions, including Weill Cor... prostate cancer. The gift is one of the largest-e...rch. , The multidisciplinary research team, creat... develop a novel nanomedicine for prostate cancer ...
...dams appear to be threatening the health of Lake V... who depend on the lake for food. A new study sugg... decreased the lake level by at least two meters b...nfluenced by weather. The study by Yustina Kiwango...ames Cook University in Australia was published on...
Other Biology News:Smithsonian study: Sediment prediction tools off the mark 2Nanomedicine research for prostate cancer supported by $5 million gift 2Nanomedicine research for prostate cancer supported by $5 million gift 3New threat to Lake Victoria? 2
The LAS-1000 plus Luminescent Image Analysis System from FUJIFILM Life Science
...he TUNEL-based assay kit provides complete compone...for convenient detection of DNA fragmentation in c...s an one-step labeling of apoptotic cells. Inter...ptosis in mammalian cells. MBLs ApoDIRECT In Situ ...
... Life Science FLA-5100 imaging system allows imagi...ge as 40 x 46cm at a pixel size as low as 10 micro... electrophoresis in the proteomics field and gener...100 includes four imaging solutions in a single sy...
... Thermocycler provides high speed and excellent te...imized with a TGradient Thermocycler can be run wi... with a silver block for 48 or 96 wells. In additi...tions are available. The High Precision Smart Lid ...
Biology Products: